{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=5", "query": { "intervention": "Single intravenous doses of placebo", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 676, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T02:44:04.880Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02127970", "title": "Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Abscess", "Wound Infection", "Surgical Site Infection", "Cellulitis" ], "interventions": [ { "name": "Dalbavancin", "type": "DRUG" }, { "name": "Dalbavancin-matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 698, "start_date": "2014-04-18", "completion_date": "2015-03-11", "has_results": true, "last_update_posted_date": "2018-09-28", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 25, "location_summary": "Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02127970" }, { "nct_id": "NCT05901883", "title": "First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "CEL383", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celsius Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 48, "start_date": "2023-06-20", "completion_date": "2024-01-17", "has_results": false, "last_update_posted_date": "2024-02-09", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05901883" }, { "nct_id": "NCT05229653", "title": "The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometriosis", "Post Operative Pain" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2022-04-12", "completion_date": "2022-10-21", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05229653" }, { "nct_id": "NCT04988035", "title": "ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Danicopan", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 201, "start_date": "2021-08-03", "completion_date": "2022-04-23", "has_results": true, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04988035" }, { "nct_id": "NCT01086540", "title": "Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis-Associated PAH" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "CMRI", "type": "DIAGNOSTIC_TEST" }, { "name": "prednisone", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 57, "start_date": "2011-06-24", "completion_date": "2019-12-15", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 17, "location_summary": "Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086540" }, { "nct_id": "NCT04471038", "title": "Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza Type A", "Influenza Type B", "Influenza" ], "interventions": [ { "name": "SAB-176", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SAb Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 27, "start_date": "2020-07-29", "completion_date": "2021-04-19", "has_results": true, "last_update_posted_date": "2025-01-06", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04471038" }, { "nct_id": "NCT04978493", "title": "A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "BI 706321", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 49, "start_date": "2021-12-02", "completion_date": "2024-08-08", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 15, "location_summary": "Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more", "locations": [ { "city": "Northridge", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Inverness", "state": "Florida" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04978493" }, { "nct_id": "NCT00925548", "title": "STRIDE - STimulating Immune Response In aDvanced brEast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tecemotide (L-BLP25) and Hormonal Treatment", "type": "BIOLOGICAL" }, { "name": "Placebo of tecemotide (L-BLP25) and Hormonal Treatment", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "sodium chloride (NaCl)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2009-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 1, "location_summary": "Hickory, North Carolina", "locations": [ { "city": "Hickory", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00925548" }, { "nct_id": "NCT05872958", "title": "Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "AZD3152", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 98, "start_date": "2023-05-19", "completion_date": "2024-08-20", "has_results": false, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 4, "location_summary": "Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05872958" }, { "nct_id": "NCT03873038", "title": "Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Dialysis", "Kidney Failure, Chronic" ], "interventions": [ { "name": "MK-2060", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 38, "start_date": "2019-04-29", "completion_date": "2021-12-20", "has_results": true, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-12T02:44:04.880Z", "location_count": 3, "location_summary": "Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03873038" } ] }